NPPB and hydrops fetalis: Furthermore, the ARNI effects on NT-proBNP are notlimited to a chronic setting but are also important in acute HF, as shown by thePIONEER-HF trial in HFrEF [70] and by the Prospective comparison of ARNI with ARBGiven following the stabiLization In DEcompensated HFpEF (PARAGLIDE) trial.However, also in the PARAGLIDE trial, sacubitril/valsartan did not reducemortality, even if the hierarchical outcome showed a positive but not significanttrend (unmatched win ratio: 1.19; 95% CI: 0.93–1.52; p = 0.16) [71](Table 2, Ref.